Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2007 June;73(6) > Minerva Anestesiologica 2007 June;73(6):371-5

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ANESTESIOLOGICA

A Journal on Anesthesiology, Resuscitation, Analgesia and Intensive Care


Official Journal of the Italian Society of Anesthesiology, Analgesia, Resuscitation and Intensive Care
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,036


eTOC

 

CASE REPORTS  


Minerva Anestesiologica 2007 June;73(6):371-5

language: English

Successful early voriconazole treatment of Aspergillus infection in two non immunocompromised patients in Intensive Care Unit

Nataloni S., Gabbanelli V., Rossi R., Donati A., Pantanetti S., Pelaia P.

Department of Anaesthesia and Intensive Care Politecnica delle Marche University, Ancona, Italy


FULL TEXT  


We report two cases of respiratory Aspergillus infection that occurred in patients admitted to the Intensive Care Unit of a teaching hospital during renovation works and treated with new triazole voriconazole (Vfend). The first patient was affected with cerebral hemorrhage, the second with polytrauma and both developed Aspergillus Pneumonia during their ICU stay. Bronchoalveolar lavage, dosage with anti-Aspergillus antibodies, antigen measurements and galactomannan research with Sanofi Platelia were performed. Therapy was carried out with voriconazole for 12 days. Chest X-ray and laboratory tests showed complete resolution after 12 days of therapy; clinical symptoms were negative after 4 days. Aspergillus infection can be observed frequently in non-immunocompromised patients during ward renovation or in hospitals near building areas. Since treatment is often unsuccessful, we preferred to immediately employ new agents to reduce the impact of this disease.

top of page

Publication History

Cite this article as

Corresponding author e-mail